de Haas SL, Slamon DJ, Martin M, Press MF, et al. Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE). Breast Cancer Res 2023;25:2.
PMID: 36631725